![](https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEjAdGjF0IPZpl2vo0muow9G44aLoP4X6Rfk7_8dywvyeplbdbg-s3R3EgdFH2kcz5fc1HrKdIho6C_BXjtQJ47X3w9IhWTNJ_4bbzF9m3Blm3raNieAo6KG1c-9lonu_YewTZTGhqijUJ4/s1600/RARE+2014-01-31+IPO+day.png)
NEW YORK (AP) -- Shares of Ultragenyx have more than doubled in their trading debut after the drug developer's initial public offering raised $121 million.
The Novato, Calif., company is developing several possible treatments for rare or extremely rare diseases, including Sly Syndrome, a cellular and organ dysfunction that typically leads to death by early adulthood.
Ultragenyx Pharmaceutical Inc. sold 5.8 million shares at $21 each, well above its mid-January forecast of 4.8 million shares going for $14 to $17.
The stock climbed $24 to $45 per share in midday trading Friday.
Two other drug developers debuted on the public market Friday: Trevena Inc., which raised about $64.8 million, and Cara Therapeutics Inc. in a $55 million IPO.
![](https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEhOkBmkPhwN0REZFlLS8eaYniwUYUPtd21PeZDtc7Inrtg2U-VtPJ1o-8CHo0bqHm4OVNtH_qRjqy8yFXlJhmM0pmHcSlkcS_qTBTTagNUBv4Eq75OcqqSBIDtCUAvSP-AqiXXwhP0sHmg/s1600/RARE+2014-02-20.png)
3 weeks after IPO
Address
60 Leveroni Court
NOVATO, CA 94949
United States
NOVATO, CA 94949
United States
Website
http://www.ultragenyx.comUltragenyx Pharmaceutical Inc., a development-stage biotechnology company, focuses on the identification, acquisition, development, and commercialization of various products for the treatment of rare and ultra-rare diseases in the United States. It develops various biologics product candidates, including KRN23, a human monoclonal antibody to bind and reduce the biological activity of fibroblast growth factor to enhance abnormally low phosphate levels in patients with X-linked hypophosphatemia; recombinant human beta-glucuronidase, an intravenous enzyme replacement therapy for the treatment of mucopolysaccharidosis 7; and recombinant human protective protein cathepsin-A, an enzyme replacement therapy for galactosialidosis. The company is also developing a range of small-molecule product candidates comprising triheptanoin, a substrate replacement therapy for patients with fatty acid oxidation disorders, as well as for patients with glucose transporter type-1 deficiency syndrome; and oral formulation of sialic acid to treat hereditary inclusion body myopathy. It has license agreements with AAI Pharma Services Corp. and HIBM Research Group; and a collaboration and license agreement with Nobelpharma Co., Ltd.
The company was founded in 2010 and is headquartered in Novato, California.
No comments:
Post a Comment